Regeneron Pharmaceuticals Inc (REGN) Stock Price

REGNStock
$833.56+40.55%52W
Market Cap$85.82B
P/E18.24x
PEG Ratio1.38
Div yield0.46%
Beta0.15

REGN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-6.66%
Price vs S&P 500 (4W)16.13%
PEG Ratio1.38
VGM Score56.63
P/E Ratio (Annual)18.24x
Indicated Dividend Yield (Annual)0.46%

REGN Earnings Surprise History

Q2 2512.89est. 8.44
Q3 2511.83est. 9.64
Q4 2511.44est. 10.75
Q1 269.47est. 8.90
Q2 2614.29est. 10.21

REGN Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.08
3.95
3.95
3.92

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
REGNRegeneron Pharmaceuticals Inc
CCB$833.56
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers and commercializes biopharmaceutical products across ophthalmology, immunology, cardiovascular disease, oncology, and rheumatology, with marketed drugs including Eylea HD, Dupixent, Praluent, Libtayo, and Kevzara. The company develops monoclonal and bispecific antibodies independently and through collaborations, including a partnership with Sanofi. Regeneron is advancing next-generation therapies through early-stage partnerships in RNAi and CRISPR-based gene editing.